Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophagitis, Reflux Clear all
Completed Phase 4 Interventional

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
esomeprazole magnesium (oral medication)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
39
States / cities
Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis

NCT00895817
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Swallowed fluticasone, Esomeprazole
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed Phase 1 Interventional

The Effect of Nexium on Transmucosal Esophageal Leak

NCT00216788
View directory record Official record
Conditions
Reflux, Esophagitis, Barrett's Esophagus
Interventions
Esomeprazole (Nexium) 40 mg/day
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2010 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
25 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

NCT00195208
View directory record Official record
Conditions
Gastroesophageal Reflux, Esophagitis
Interventions
Pantoprazole for approximately 9 weeks
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Jul 21, 2026, 2:19 PM EDT
Enrolling by invitation No phase listed Observational

The Johns Hopkins Heartburn Center Registry

NCT03853772
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Barrett Esophagus, Laryngopharyngeal Reflux, Esophagitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Orange, California • Baltimore, Maryland • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

NCT00539240
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251719
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Esophageal Monitoring Device for Assessing Mucosal Impedance

NCT01556919
View directory record Official record
Conditions
GERD, Esophagitis
Interventions
Standard of care endoscopy
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Not applicable Interventional

Quantifying Effects of Treatment of Pediatric Dysphonia

NCT00237679
View directory record Official record
Conditions
Voice Disorders, Gastroesophageal Reflux
Interventions
Neuromuscular Electrical Stimulation, Unstimulated
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)

NCT03228407
View directory record Official record
Conditions
Gastro Esophageal Reflux, Barrett Esophagus, Erosive Esophagitis
Interventions
Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI)
Procedure · Diagnostic Test
Lead sponsor
McGuire Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 3 Interventional

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05267613
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Nexium 20mg, Nexium 10mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 3 Interventional

Domperidone in Treating Patients With Gastrointestinal Disorders

NCT01696734
View directory record Official record
Conditions
Digestive System Disorder, Dyspepsia, Esophagitis, Gastroesophageal Reflux Disease, Gastroparesis, Heartburn, Nausea and Vomiting
Interventions
Domperidone, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Indiana University Gastrointestinal Motility Diagnosis Registry

NCT04506593
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Gastroparesis, Functional Vomiting, Irritable Bowel Syndrome (IBS), Constipation, Chronic Intestinal Pseudo-obstruction, Fecal Incontinence, Small Intestinal Bacterial Overgrowth
Interventions
no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed Not applicable Interventional

Domperidone for Refractory Gastrointestinal Disorders

NCT00777439
View directory record Official record
Conditions
Gastroparesis
Interventions
Domperidone
Drug
Lead sponsor
Arnold, George, M.D.
Individual
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies

NCT02038894
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation, Propofol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 12 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

NCT06831344
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use

NCT01306799
View directory record Official record
Conditions
Barrett's Esophagus, Erosive Esophagitis, Gastroesophageal Reflux Disease(GERD)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 21, 2026, 2:19 PM EDT